ViaDerma (VDRM)
OTHER OTC:VDRM
Want to see VDRM full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong demand for ViaDerma's products and successful market penetration, supporting long-term business expansion.
Negative Factors
Declining Net Profit Margins
Declining net profit margins suggest rising expenses or inefficiencies, which could impact ViaDerma's long-term profitability and financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong demand for ViaDerma's products and successful market penetration, supporting long-term business expansion.
Read all positive factors
ViaDerma (VDRM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$493.49K
Dividend YieldN/A
Average Volume (3M)581.10K
Price to Earnings (P/E)―
Beta (1Y)-3.07
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,233,713,100
10 Day Avg. Volume428,867
30 Day Avg. Volume581,103
Financial Highlights & Ratios
PEG Ratio-30.47
Price to Book (P/B)101.36
Price to Sales (P/S)20.79
P/FCF Ratio71.33K
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue1.79
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-6.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ViaDerma Business Overview & Revenue Model
Company Description
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeu...
How the Company Makes Money
ViaDerma generates revenue through the commercialization and sales of its proprietary topical products, particularly Vitastem. The company earns money by directly selling its products to healthcare providers, pharmacies, and distributors. Addition...
ViaDerma Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 450.74K | 600.50K | 540.65K | 514.01K | 11.47K | 10.39K |
| Gross Profit | 450.60K | 600.30K | 540.45K | 511.33K | 10.83K | 9.86K |
| EBITDA | -130.61K | 80.71K | 689.84K | -882.91K | -282.60K | -338.07K |
| Net Income | -194.16K | 4.10K | 590.67K | -994.18K | -431.67K | -599.27K |
Balance Sheet | ||||||
| Total Assets | 4.07M | 1.28M | 713.98K | 275.02K | 123.03K | 69.22K |
| Cash, Cash Equivalents and Short-Term Investments | 1.49M | 10.24K | 10.07K | 11.56K | 10.13K | 9.90K |
| Total Debt | 1.86M | 322.94K | 415.18K | 415.18K | 588.60K | 769.60K |
| Total Liabilities | 4.22M | 1.16M | 2.56M | 2.71M | 2.31M | 3.07M |
| Stockholders Equity | -144.40K | 123.15K | -1.84M | -2.44M | -2.19M | -3.00M |
Cash Flow | ||||||
| Free Cash Flow | -506.81K | 175.00 | -1.49K | 1.43K | -8.77K | -15.12K |
| Operating Cash Flow | -506.81K | 175.00 | -1.49K | 1.43K | -8.77K | -15.12K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.54M | 0.00 | 0.00 | 0.00 | 9.00K | 15.00K |
ViaDerma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $493.49K | -3.44 | ― | ― | ― | ― | |
46 Neutral | $2.09M | -1.90 | -85.94% | ― | 26.83% | 48.18% | |
45 Neutral | $21.48M | -1.06 | -43.00% | ― | -8.49% | 72.59% | |
42 Neutral | $1.64M | ― | ― | ― | ― | ― | |
| ― | $3.82M | -0.28 | -9999.00% | ― | ― | 85.99% |
* Healthcare Sector Average
VDRM
ViaDerma
0.01
0.00
0.00%
CPHI
China Pharma Holdings
0.53
-1.59
-75.00%
SNOA
Sonoma Pharmaceuticals
1.20
-1.95
-61.90%
PRFX
PainReform
1.94
-7.36
-79.14%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.69
-5.12
-88.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―